Results from a phase III clinical trial (BOSTON) evaluating selinexor (Xpovio®) in combination with bortezomib (Velcade®) and dexamethasone for the treatment of relapsed or refractory myeloma patients have been published in the Lancet. The data provide evidence to support the use of selinexor for the treatment of relapsed or refractory myeloma patients who had received…
Myeloma UK has initiated a project to analyse the results of the England 2018 National Cancer Patient Experience Survey to better understand the myeloma patient experience. The National Cancer Patient Experience Survey provides a snapshot of patients’ experience of NHS care, from the information they receive to how well they feel their care is delivered.…
The year so far has been particularly busy for the myeloma access pipeline with four new myeloma treatments being appraised by both drug approval bodies, the National Institute for Healthcare Excellence (NICE) and the Scottish Medicines Consortium (SMC). There is also a new treatment for patients with AL Amyloidosis which has begun the appraisal process…
Myeloma UK have developed a series of Digital Infoday Sessions to continue providing information and support to patients following the cancellation of our usual Infoday events programme. The online events take place in a variety of formats, each lasting one hour. This includes panel discussions, Q & A sessions and presentations each centred around a…
Myeloma UK are passionate about ensuring patients have access to the treatments that are right for them. As a result, one of the aims of a recent project in our Health Services Research Programme was to understand how myeloma patients choose between different treatment options and identify what treatment attributes are most important to them.…
Myeloma UK have developed an information hub to help keep patients up to date with the latest news on COVID-19. The COVID-19 Information Hub is a one stop shop for information about the COVID-19 pandemic and how it is affecting patients’ treatment and care. The Hub is being regularly updated with the latest news and guidance from the UK Government…
The response to the COVID-19 pandemic has put the UK Government and NHS on an emergency footing. With this substantial change to NHS services, there has been a rapid growth in published guidelines and policy to help Healthcare Professionals (HCPs) ensure patients get the right treatment and care. Here we have detailed some key sources…
The 61st American Society of Hematology Annual Meeting (ASH) took place on 7-10 December in Orlando, Florida. It was attended by over 30,000 scientists and clinicians from around the world and covered around 6,000 topics with over 700 myeloma abstracts. Here are some of our highlights from this year’s meeting. Myeloma XI There were five…
The 61st American Society of Hematology Annual Meeting (ASH) took place on 7-10 December in Orlando, Florida. Our Director of Research Sarah McDonald and Director of Healthcare Advocacy Services Ira Laketic-Ljubojevic attended to learn about the latest myeloma research and see the progress from Myeloma UK funded research. Results from research part-funded by Myeloma UK, the…
The way evidence is used to approve new treatments for use on the NHS is set to change, under a review being carried out by the National Institute for Health and Care Excellence (NICE). The review of methods, running throughout 2020, is an opportunity to address some of the challenges in approving treatments: for example, ensuring…
